Inhibitors of parp activity and uses thereof

Details Inhibitors of parp activity and uses thereof Inhibitors of parp activity and uses thereof

A - Human Necessities

61

K

A61K 38/17 (2006.01) A61P 9/00 (2006.01) A61P 25/00 (2006.01) A61P 31/18 (2006.01) A61P 35/00 (2006.01) C07K 14/47 (2006.01) C12N 15/62 (2006.01) C12N 15/63 (2006.01)

Patent

CA 2629376

The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5'- diphospho-ribose) polymerase ["poly(ADP-ribose) polymerase" or "PARP", which is also sometimes called "PARS" for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

La présente invention concerne de nouveaux inhibiteurs de l~enzyme nucléique polymérase poly(adénosine 5'- diphospho-ribose) et/ou de polymérase poly(ADP-ribose) ou ~PARP~, qu~on appelle aussi parfois ~PARS~ pour la poly(ADP-ribose) synthétase]. L~invention a plus particulièrement trait à l~utilisation d~inhibiteurs PARP pour empêcher et/ou traiter l~endommagement de tissus qui résulte d~endommagements de cellules ou d~une mort due à une nécrose ou une apoptose ; l~endommagement de tissus neuraux résultant d~une ischémie et d~une lésion de reperfusion, des désordres neurologiques et neurodégénératifs ; pour empêcher ou traiter un accident vasculaire cérébral ou des désordres cardiovasculaires, pour traiter d~autres conditions et/ou désordres tels qu~une dégénération maculaire découlant de l~âge, le SIDA et autre maladies de senescence immunitaire, l~arthrite, l~athérosclérose, la cachexie, le cancer, les maladies dégénératives des muscles implicant une senescence réplicative, le diabète, les lésions traumatiques à la tête, la senescence immunitaire, les désordres intestinaux inflammatoires (tels que la et la maladie de Chrohn) la dystrophie musculaire, l~ostéoarthrite, l~ostéoporose, une douleur chronique et aigüe (telle qu~une douleur neuropathique), une insuffisance rénale, une ischémie rétinale, un chock septique (tel qu~un choc endotoxique) et le vieillissement de la peau ; pour prolonger la vie et la capacité de prolifération des cellules, pour altérer l'expression de gènes des cellules senescentes ou pour radiosensibiliser les cellules tumorales hypoxiques.

Affiliated with

Also associated with

Rating

Inhibitors of parp activity and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of parp activity and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of parp activity and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1839011